AI assistant
SELLAS Life Sciences Group, Inc. — Director's Dealing 2016
Nov 16, 2016
33651_dirs_2016-11-15_42861aa3-f472-4eac-b98c-3719cb35f512.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2016-11-01
Reporting Person: Ghiglieri Stephen F (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-11-01 | Stock Option (right to buy) | $0.19 | A | 1000000 | Acquired | 2026-11-01 | Common Stock (1000000) | Direct |
Footnotes
F1: Granted pursuant to the Issuer's 2016 Incentive Plan.
F2: The Reporting Person obtained the securities pursuant to a new hire Employment Agreement dated November 1, 2016. The securities were convertible into common stock at the rate of 1 share of common stock for each 1 stock option share, or an aggregate 1,000,000 shares of common stock (pre-reverse stock split). The securities were converted into 50,000 stock options at a price of $3.80 (post-reverse stock split) as of November 14, 2016.
F3: This stock option vests in equal, quarterly installments over four years, beginning three months after November 1, 2016.